Want to see AU:ZLD full AI Analyst Report?
Zelira Therapeutics (ZLD) AI Stock Analysis
Zelira Therapeutics
(ASX:ZLD)
Zelira Therapeutics' score of 52 reflects significant financial weaknesses, including revenue decline, negative equity, and cash burn, which heavily weigh down the outlook. Positive technical momentum provides some upside, but speculative valuation limits confidence. Caution is advised.
Zelira Therapeutics (ZLD) vs. iShares MSCI Australia ETF (EWA)
- Market Cap
- AUD 131.47K
- Dividend Yield
- ―
- Average Volume (3M)
- ―
- Price to Earnings (P/E)
- -1.6
- Beta (1Y)
- 1.64
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- Australia
- Employees
- 8
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Zelira Therapeutics Business Overview & Revenue Model
Company Description
Zelira Therapeutics Limited (ZLD.AX) is an Australian biopharmaceutical firm dedicated to the research, development, and commercialization of cannabinoid-derived medicines for a variety of medical conditions. Its product portfolio includes HOPEâ„¢ bran...
How the Company Makes Money
Zelira’s monetization has historically been intended to come from a mix of (1) commercialization of proprietary cannabinoid-based products (including consumer health/wellness products) through sales via distribution and retail/online channels, and (2...
Zelira Therapeutics Financial Statement Overview
Summary
Zelira Therapeutics exhibits severe financial challenges with a drastic revenue decline (-98.4%), deeply negative margins (Net Profit Margin -5530.3%), negative equity (-4.46M), and persistent cash burn (-4.91M Operating Cash Flow). While common in biotech, the lack of growth and high leverage signal significant risk.
Income Statement
10Very NegativeBalance Sheet
15Very NegativeCash Flow
20Very Negative| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 656 | 656 | 94.95K | 301.12K | 1.54M | 663.32K |
| Gross Profit | -802.95K | -802.95K | 10.28K | -3.22M | -5.72M | -39.16K |
| EBITDA | -4.05M | -4.05M | -36.44M | -6.79M | -13.06M | -9.41M |
| Net Income | -3.63M | -3.63M | -36.57M | -5.57M | -11.95M | -8.55M |
Balance Sheet | ||||||
| Total Assets | 1.30M | 1.30M | 5.18M | 33.89M | 37.70M | 39.37M |
| Cash, Cash Equivalents and Short-Term Investments | 5,663 | 5,663 | 586.16K | 146.21K | 2.75M | 4.97M |
| Total Debt | 2.14M | 2.14M | 5.95M | 437.90K | 500.91K | 551.08K |
| Total Liabilities | 5.59M | 5.59M | 9.36M | 2.18M | 2.01M | 1.54M |
| Stockholders Equity | -4.46M | -4.46M | -4.51M | 31.80M | 35.20M | 37.83M |
Cash Flow | ||||||
| Free Cash Flow | -4.91M | -4.91M | -4.39M | -7.25M | -9.43M | -8.62M |
| Operating Cash Flow | -4.91M | -4.91M | -4.39M | -7.25M | -9.43M | -8.62M |
| Investing Cash Flow | 1.15M | 1.15M | 919.74K | 2.83M | -207.78K | 1.38M |
| Financing Cash Flow | 3.19M | 3.19M | 3.92M | 1.77M | 7.10M | 10.53M |
Zelira Therapeutics Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:ZLD, the sentiment is Negative. The current price of 0.50 is below the 20-day moving average (MA) of 0.50, above the 50-day MA of 0.50, and below the 200-day MA of 0.52, indicating a neutral trend. The MACD of -0.00 indicates Negative momentum. The RSI at 38.50 is Neutral, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:ZLD.
Zelira Therapeutics Peers Comparison
Overall Rating
- AU:ZLD52Neutral
AU:PAR47Neutral
AU:ACW44Neutral
AU:ENP43Neutral
AU:BOT41Neutral
AU:ILA30.5Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| AU:ZLD | 52Neutral | AUD 5.95M | -1.56 | 80.84% | ― | ― | ― |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| AU:PAR | 47Neutral | AUD 153.48M | -1.61 | -1189.87% | ― | 53.78% | -206.24% |
| AU:ACW | 44Neutral | AUD 162.72M | -8.75 | -103.42% | ― | ― | 5.88% |
| AU:ENP | 43Neutral | AUD 50.66M | -13.48 | -63.60% | ― | ― | 29.55% |
| AU:BOT | 41Neutral | AUD 27.63M | -0.31 | -118.74% | ― | 499.47% | 31.20% |
| AU:ILA | 31Underperform | AUD 85.87M | -8.05 | -95.50% | ― | ― | -59.29% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| AU:ZLD | Zelira Therapeutics Ltd. | 0.50 | 0.13 | 35.14% | |
| AU:ACW | Actinogen Medical Limited | 0.04 | 0.00 | 5.00% | |
| AU:ENP | Tryptamine Therapeutics Limited | 0.03 | -0.01 | -18.42% | |
| AU:PAR | Paradigm Biopharmaceuticals Ltd. | 0.24 | -0.16 | -39.51% | |
| AU:ILA | Island Pharmaceuticals Ltd | 0.29 | -0.14 | -32.56% | |
| AU:BOT | Botanix Pharmaceuticals Limited | 0.01 | -0.12 | -92.31% |
Zelira Therapeutics Corporate Events
Zelira Secures US$33m for HOPE® 1 SPV to Advance FDA Autism Trial
Zelira Therapeutics has secured definitive agreements for a US$32.98 million capital raise into its HOPE® 1 special purpose vehicle, valuing the SPV at about US$65.96 million and Zelira’s post-money stake at roughly US$26.19 million. On a...
ASX Sets Deadlines for Long-Term Suspended Companies Facing Delisting Risk
The ASX has issued a market announcement listing entities whose securities have been suspended from trading for more than three months, detailing for each the outstanding periodic financial and activity reports and the deadlines by which these docume...
Zelira Director Converts Convertible Notes, Boosting Equity Stake
Zelira Therapeutics has disclosed a change in director Osagie Imasogie’s interests following the conversion of a portion of his convertible notes into ordinary shares. Imasogie acquired 1,250,000 shares at US$0.40 per share through note convers...
Zelira Therapeutics Ceases 2.25 Million Convertible Notes
Zelira Therapeutics has notified the market of the cessation of 2,250,000 ZLDAM convertible notes, effective 29 June 2026, under an Appendix 3H filing. The removal of these convertible notes alters the company’s issued capital profile and may m...
Zelira Therapeutics Seeks ASX Quotation for 1.25 Million New Shares
Zelira Therapeutics has applied for quotation on the ASX of 1,250,000 new fully paid ordinary shares, which were issued on July 1, 2026. The additional securities expand the company’s quoted share capital, potentially improving liquidity in its...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Jan 21, 2026